Hepatitis C Associated B-cell Non-Hodgkin Lymphoma:Clinical Features and the Role of Antiviral Therapy
Hepatitis C Associated B-cell Non-Hodgkin Lymphoma:Clinical Features and the Role of Antiviral Therapy作者机构：Department of Surgery St.Luke's Center for Liver Disease Baylor College of Medicine Houston Texas USA Department of Surgery St.Luke's Center for Liver Disease Baylor College of Medicine Houston Texas USA Department of Gastroenterology and Hepatology Baylor College of Medicine Houston Texas USA
出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)
年 卷 期：2015年第3卷第2期
页 面：134-139页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Hepatitis C Non-Hodgkin lymphoma Mixed cryoglobulinemia Rituximab
摘 要：The link between chronic hepatitis C virus (HCV) infection and a subset of B-cell non-Hodgkin lymphomas (B-NHL) is strongly supported by epidemiological *** demonstrating complete regression of lymphoma after antiviral treatments suggests possible chronic antigenic stimulation for the origin of B-NHL and provides evidence for a virus-mediated lymphomagenesis.B-NHL is a heterogeneous group of lymphomas with varied clinical presentation and may be indolent or *** optimal management of HCV related B-NHL is not *** treatment may be sufficient for low-grade lymphomas,but chemotherapy is necessary in patients with high grade *** (IFN)-based antiviral treatment regimens for HCV infection are limited by poor tolerance and suboptimal antiviral *** approved novel direct acting antiviral (DAA) drugs are highly effective and *** has opened a new era for the treatment of HCV related B-NHL alone or in conjunction with *** of HCV associated B-NHL should be performed in an interdisciplinary approach in close consultation with hematologist and *** this review,we summarize data regarding clinical features and epidemiology of B-NHL and discuss novel therapeutic approaches,including DAAs,that may prove to be effective in the treatment of HCV associated lymphomas.
维普期刊数据库